A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept

Rheumatol Int. 2014 Mar;34(3):443-4. doi: 10.1007/s00296-012-2617-8. Epub 2012 Dec 22.

Authors

Özgür Akgül¹, Gamze Kılıç, Erkan Kılıç, İsa Cüce, Salih Özgöçmen

Affiliation

¹ Department of PMR, Division of Rheumatology, Erciyes University, Faculty of Medicine, Kayseri, Turkey, ozgur.akgul.md@gmail.com.

PMID: 23263496
DOI: 10.1007/s00296-012-2617-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / adverse effects
Antirheumatic Agents / therapeutic use
Dose-Response Relationship, Drug
Etanercept
Female
Humans
Immunoglobulin G / therapeutic use*
Infliximab
Lupus Erythematosus, Systemic / chemically induced*
Lupus Erythematosus, Systemic / diagnosis
Receptors, Tumor Necrosis Factor / therapeutic use*
Spondylitis, Ankylosing / drug therapy*
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Withholding Treatment

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Infliximab
Etanercept